Special Issue "Edaravone for the Treatment of Amyotrophic Lateral Sclerosis"
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 4184
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Most patients die within 3–5 years from onset. All ALS patients are desperate for new treatment. It took almost 20 years after riluzole approval in 1995 until edaravone was approved in Japan in 2015 and in US in 2017. Although the first phase 3 trial collecting a wide variety of ALS patients failed to show the efficacy of edaravone, the second phase 3 trial succeeded in proving its efficacy in inhibiting the deterioration of motor functions by approximately 33% compared to placebo. The results of these clinical trials tell us early diagnosis is critically important for the benefit of ALS patients to prolong better motor functions for longer. Development of biomarkers for early diagnosis is critically important. At present, edaravone is limited to intravenous administration. The oral formula of edaravone is under clinical trial for 12 months of safety assessment. In order to investigate more efficacious edaravone treatment options, a double-blind study is being launched to show the efficacy of everyday administration compared to current protocol with 10 days in 4 weeks administration. As free radical scavenging has been proven to be a key treatment strategy, further development of new therapeutic agents that target free radicals could lead to better outcomes for ALS treatment.
Dr. Hiide Yoshino
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- free radicals
- oxidative stress
- clinical trial